

Working together, for a more competitive, healthier and stronger Europe & Japan


















EFPIA's vision: working together for a more competitive, healthier and stronger Europe and Japan

Industry contributing to patients, healthcare systems and societies overall

COMPETITIVE

HEALTHIER

STRONGER



THRIVING EUROPEAN –
AND JAPANESE
INNOVATION ECOSYSTEM
FOR MEDICINES



ALL PEOPLE IN EUROPE AND JAPAN HAVE TIMELY ACCESS TO WORLD LEADING CARE AND THERAPEUTICS



A PHARMACEUTICAL
SECTOR THAT
CONTRIBUTES TO A
SUSTAINABLE SOCIETY
AND ECONOMY






Because the healthcare sector is transforming, more than ever, meaningful patient engagement is a priority for EFPIA

IN EUROPE

- * A Patient engagement strategy is endorsed by the EFPIA board and is priority area under our strategic goal of 'contributing to a sustainable society and economy'
- EFPIA has worked to ensure that the voice of patient organisations is heard across the life-cycle of a medicine, at every decision-making point including through: EFPIA Patient Think Tank and Innovative Medicines Initiative
- * We have co-created a number of collaborative projects in areas of common interest such as (#DatasavesLives), HTA 360 project
- * To Ensure the highest standards of ethics, EFPIA has co-created a set of principles to govern relationships between patient organisations and the pharmaceutical industry

IN JAPAN



■当事者の取り巻く背景や困りごとを推測し考えるワークショップ「難病/ ルソナワークショップ | の開発

業務との両立について、適正な理解と合理的配慮について考える機会を提供

いるか、働く上でどのような困難があるのかを想像し、考えてもらう ・考えた内容をまとめて、どうすれば誰もが働きやすい環境になるかを共に考えて一人ひ とりどう行動するかを発表してもらう

・ペルソナを就労までと、就労してから2つのジャーニーマップを作成

支援者も交えて、ワークショップのチームは何名が適正か、ペルソナカードの選び方を どうするか、効果測定をどうするかGo liveに向けたプレワークショップを2回実施

活動により

・提供先企業でのマインドセットの変化:初年度計画を7社140名とし、最終的に

50社1000名以上の経営層・HR等の主要部署への提供を目標

・心理的安全性の醸成



The European-based biopharma companies have been working closely with various governments in co-developing life-sciences strategies

FRANCE




'France Innovation Health' 2030 is established in a concerted manner between the State and the pharmaceutical, device and diagnostic sectors. The strategic vision is co-constructed on the basis of shared diagnosis and challenges, and the operational follow-up of the measures is then ensured by people from the industrial sector with regular meetings with the different ministries concerned (health, industry, research) and Macron's office.



The interministerial mission under the PM Elisabeth Borne on the regulation and financing of health products calls for a "New Deal", enabling an equal and sustainable access for all patients to pharamceutical products. The report believes that innovation in general, and health data in particular are "key to finding financial margins and therefore cost and volume control". The mission recalls that innovation can help control public spending in certain areas.

DENMARK






The Danish National Life Sciences Council enables continuous alignment on key policy goals between various stakeholders, including industry, government stakeholders, and patient organizations.

As in Europe, EFPIA is committed to working closely with Japanese government to co-develop a pro-innovation health-ecosystem

Pre and pandemic phase key learnings



NUMBER OF NEW CHEMICAL AND BIOLOGICAL ENTITIES (2001-2020)



New post-pandemic Health Policies



As in Europe, a substantial, high-level strategic dialogue is needed and can significantly contribute to a renewed collaboration for health in Japan





Thank you! ありがとうございました!

























